These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36315917)

  • 1. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With
    Gupta R; Meric-Bernstam F; Rothe M; Garrett-Mayer E; Mangat PK; D'Andre S; Ahn ER; O'Lone R; Halabi S; Grantham GN; Schilsky RL
    JCO Precis Oncol; 2022 Oct; 6():e2200306. PubMed ID: 36315917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With
    Ahn ER; Rothe M; Mangat PK; Garrett-Mayer E; Ali-Ahmad HM; Chan J; Maitland ML; Patel SR; Reese Z; Balmanoukian AS; Drescher CW; Li R; Tsimberidou AM; Leath CA; O'Lone R; Grantham GN; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Apr; 7():e2200609. PubMed ID: 37027810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With
    Ganti AK; Rothe M; Mangat PK; Garrett-Mayer E; Dib EG; Duvivier HL; Ahn ER; Behl D; Borghaei H; Balmanoukian AS; Gaba A; Li R; Osei-Boateng K; Thota R; Grantham GN; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Jun; 7():e2300041. PubMed ID: 37315265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With
    Cannon TL; Rothe M; Mangat PK; Garrett-Mayer E; Chiu VK; Hwang J; Vijayvergia N; Alese OB; Dib EG; Duvivier HL; Klute KA; Sahai V; Ahn ER; Bedano P; Behl D; Sinclair S; Thota R; Urba WJ; Yang ES; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    J Clin Oncol; 2024 May; ():JCO2302078. PubMed ID: 38748939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With
    Klute KA; Rothe M; Garrett-Mayer E; Mangat PK; Nazemzadeh R; Yost KJ; Duvivier HL; Ahn ER; Cannon TL; Alese OB; Krauss JC; Thota R; Calfa CJ; Denlinger CS; O'Lone R; Halabi S; Grantham GN; Schilsky RL
    JCO Precis Oncol; 2022 Nov; 6():e2200191. PubMed ID: 36409971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Duvivier HL; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Al Baghdadi T; Alva AS; Dublis SA; Cannon TL; Calfa CJ; Li R; Behl D; Chiu VK; Gold PJ; Marr AS; Mileham KF; Powell SF; Rodon J; Thota R; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
    J Clin Oncol; 2023 Nov; 41(33):5140-5150. PubMed ID: 37561967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib in Patients With Metastatic Prostate Cancer With
    Yang ES; Halabi S; Rothe M; Garrett-Mayer E; Mangat PK; Pisick E; Dib E; Burgess EF; Zakem M; Rohatgi N; Bilen MA; O'Lone R; Grantham GN; Schilsky RL
    JCO Precis Oncol; 2023 Feb; 7():e2200505. PubMed ID: 36753688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
    Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
    JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib in Patients With Breast Cancer With
    Calfa CJ; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Burness ML; Gogineni K; Rohatgi N; Al Baghdadi T; Conlin A; Gaba A; Hamid O; Krishnamurthy J; Gavini NJ; Gold PJ; Rodon J; Rueter J; Thota R; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Feb; 8():e2300513. PubMed ID: 38354330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With
    Rohatgi N; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Pisick E; Alese OB; Reynolds CM; Thota R; Vaccaro GM; von Mehren M; Arend RC; Chiu VK; Duvivier HL; Gold PJ; Hack K; Marr AS; Winer A; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Sep; 7():e2300279. PubMed ID: 38039429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palbociclib in Patients With Soft Tissue Sarcoma With
    Schuetze S; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Calfa CJ; Farrington LC; Livingston MB; Wentzel K; Behl D; Kier Y; Marr AS; von Mehren M; Press JZ; Thota R; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Jul; 8():e2400219. PubMed ID: 39013131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Rugo HS; Im SA; Cardoso F; Cortés J; Curigliano G; Musolino A; Pegram MD; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Kaufman B; Yerushalmi R; Fasching PA; Nordstrom JL; Bonvini E; Koenig S; Edlich S; Hong S; Rock EP; Gradishar WJ;
    JAMA Oncol; 2021 Apr; 7(4):573-584. PubMed ID: 33480963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
    Takahashi K; Ishibashi E; Kubo T; Harada Y; Hayashi H; Kano M; Shimizu Y; Shirota H; Mori Y; Muto M; Ishioka C; Dosaka-Akita H; Matsubara H; Nishihara H; Sueoka-Aragane N; Toyooka S; Hirakawa A; Tateishi U; Miyake S; Ikeda S
    Medicine (Baltimore); 2020 Aug; 99(32):e21457. PubMed ID: 32769873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring
    Mazieres J; Lafitte C; Ricordel C; Greillier L; Negre E; Zalcman G; Domblides C; Madelaine J; Bennouna J; Mascaux C; Moro-Sibilot D; Pinquie F; Cortot AB; Otto J; Cadranel J; Langlais A; Morin F; Westeel V; Besse B
    J Clin Oncol; 2022 Mar; 40(7):719-728. PubMed ID: 35073148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
    Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
    JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
    Javle M; Borad MJ; Azad NS; Kurzrock R; Abou-Alfa GK; George B; Hainsworth J; Meric-Bernstam F; Swanton C; Sweeney CJ; Friedman CF; Bose R; Spigel DR; Wang Y; Levy J; Schulze K; Cuchelkar V; Patel A; Burris H
    Lancet Oncol; 2021 Sep; 22(9):1290-1300. PubMed ID: 34339623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib in Patients With Non-Small-Cell Lung Cancer With
    Ahn ER; Mangat PK; Garrett-Mayer E; Halabi S; Dib EG; Haggstrom DE; Alguire KB; Calfa CJ; Cannon TL; Crilley PA; Gaba AG; Marr AS; Sangal A; Thota R; Antonelli KR; Islam S; Rygiel AL; Bruinooge SS; Schilsky RL
    JCO Precis Oncol; 2020 Nov; 4():757-766. PubMed ID: 35050752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.